1. Home
  2. BCAB vs NAAS Comparison

BCAB vs NAAS Comparison

Compare BCAB & NAAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCAB
  • NAAS
  • Stock Information
  • Founded
  • BCAB 2007
  • NAAS 2019
  • Country
  • BCAB United States
  • NAAS China
  • Employees
  • BCAB N/A
  • NAAS N/A
  • Industry
  • BCAB Medicinal Chemicals and Botanical Products
  • NAAS Other Specialty Stores
  • Sector
  • BCAB Health Care
  • NAAS Consumer Discretionary
  • Exchange
  • BCAB Nasdaq
  • NAAS Nasdaq
  • Market Cap
  • BCAB 96.2M
  • NAAS 54.6M
  • IPO Year
  • BCAB 2020
  • NAAS 2017
  • Fundamental
  • Price
  • BCAB $2.08
  • NAAS $3.05
  • Analyst Decision
  • BCAB Strong Buy
  • NAAS
  • Analyst Count
  • BCAB 2
  • NAAS 0
  • Target Price
  • BCAB $6.00
  • NAAS N/A
  • AVG Volume (30 Days)
  • BCAB 1.6M
  • NAAS 179.6K
  • Earning Date
  • BCAB 11-08-2024
  • NAAS 11-05-2024
  • Dividend Yield
  • BCAB N/A
  • NAAS N/A
  • EPS Growth
  • BCAB N/A
  • NAAS N/A
  • EPS
  • BCAB N/A
  • NAAS N/A
  • Revenue
  • BCAB N/A
  • NAAS $58,241,066.00
  • Revenue This Year
  • BCAB N/A
  • NAAS $19.53
  • Revenue Next Year
  • BCAB N/A
  • NAAS $151.36
  • P/E Ratio
  • BCAB N/A
  • NAAS N/A
  • Revenue Growth
  • BCAB N/A
  • NAAS 199.95
  • 52 Week Low
  • BCAB $1.14
  • NAAS $1.42
  • 52 Week High
  • BCAB $4.02
  • NAAS $61.60
  • Technical
  • Relative Strength Index (RSI)
  • BCAB 55.80
  • NAAS 42.32
  • Support Level
  • BCAB $1.87
  • NAAS $3.00
  • Resistance Level
  • BCAB $2.13
  • NAAS $3.35
  • Average True Range (ATR)
  • BCAB 0.12
  • NAAS 0.24
  • MACD
  • BCAB 0.00
  • NAAS -0.03
  • Stochastic Oscillator
  • BCAB 68.90
  • NAAS 20.00

About BCAB BioAtla Inc.

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.

About NAAS NaaS Technology Inc.

Naas Technology Inc is an electric vehicle charging service provider in China, whose vision is to power the world with carbon-neutral energy. It offers an integrated set of online solutions to charging station operators. wide range of offline services that simplify the daily operations of charging station operators, and of non-charging services such as food and beverage services to station operators.

Share on Social Networks: